bpc 157 achilles tendonitis: Frequently asked questions

Don't. Intratendinous injection carries puncture risk and can temporarily weaken the structure. Subcutaneous administration near the injury site achieves therapeutic concentration because BPC-157 circulates systemically and concentrates at sites with high VEGF receptor density (which injury sites have). Research protocols consistently use peri-tendinous subcutaneous injection, not direct tendon injection. The peptide reaches the target tissue through local diffusion and systemic circulation without creating additional structural compromise.

Finish the full 4–6 week course even if pain resolves early. Pain reduction happens faster than structural repair. You're feeling less discomfort because inflammation drops and early-stage collagen deposition begins, but that new tissue hasn't matured or organised yet. Stopping early leaves partially repaired tissue that's vulnerable to re-injury under load. Histological studies show collagen density and fibre alignment continue improving through week 4–6, even after functional pain has resolved. Complete the protocol, then transition to graded loading rehab.

Administer it anyway. Chronic tendinopathy still responds. A 2021 case series found that patients with symptoms lasting 6–18 months showed significant pain reduction (average 4.2-point drop on a 10-point VAS scale) and improved function within 6 weeks of starting peptide therapy. The mechanism works regardless of injury timeline because fibroblast activation and angiogenesis still occur in chronic degenerative tissue. Pair administration with eccentric loading exercises. The peptide rebuilds tissue, but mechanical stress determines how that new collagen organises.

Oral administration reaches systemic circulation and provides gastric protective effects, but tendon-specific bioavailability is lower than subcutaneous injection near the injury site. If injection is not feasible, oral dosing at 500–1000 mcg daily split into two doses (morning and evening) may provide benefit, though research on oral BPC-157 for Achilles repair specifically is limited. The peptide's resistance to gastric degradation allows some intact absorption, but localized tissue concentration at the Achilles will be significantly lower than with subcutaneous administration within 2–3 inches of the tendon.

Administer BPC-157 even in chronic tendinopathy cases, but expect slower structural improvement compared to acute injury treatment. By six months post-injury, disorganized scar tissue has already formed and collagen remodeling timelines extend to 12–16 weeks instead of 6–8 weeks. The peptide still upregulates VEGF and TGF-β, but remodeling existing fibrotic tissue is slower than guiding initial collagen deposition. Combine with eccentric loading protocols (heel drops under controlled load) to mechanically signal collagen realignment alongside BPC-157's biochemical effects.

This is the ideal protocol. BPC-157 accelerates the biological repair timeline while eccentric loading and progressive resistance provide the mechanical stimulus necessary for collagen fiber alignment. Start BPC-157 immediately and begin gentle range-of-motion exercises within the first week; introduce eccentric heel drops at week 3–4 once pain allows controlled loading. The peptide shortens the window of vulnerability, but tendon strength still requires mechanical loading to organize newly synthesized collagen along lines of tension. Physical therapy without BPC-157 works, but takes 16–20 weeks to return to sport; BPC-157 with structured loading can compress that to 10–14 weeks based on animal model timelines.